Meeting
2020 ASCO Virtual Scientific Program
Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma.
Authors
Jerome Galon
HalioDx, Marseille, France
Jerome Galon , Nathalie Scholler , Regis Perbost , Sarah Turcan , Corinne Danan , Frederick Lundry Locke , Sattva Swarup Neelapu , David Bernard Miklos , Caron A. Jacobson , Lazaros J. Lekakis , Yi Lin , Armin Ghobadi , Justin Chou , Zixing Wang , Allen Xue , John M. Rossi , Adrian Bot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3022)
DOI
10.1200/JCO.2020.38.15_suppl.3022
Abstract #
3022
Poster Bd #
86
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
First Author: Jerome Galon
Poster
2017 ASCO Annual Meeting
Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel).
First Author: Frederick Lundry Locke
Poster
2022 ASCO Annual Meeting
Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
First Author: Paolo Strati